Public (Nasdaq: NAUT); product launch delayed to 2026, 16% layoffs (2025)
Live · NAUT· NasdaqCM
as of 2026-09-17
$0.972▼ 1.85% today
≈ $124 Million market cap · −91.8% from peak
The rise & fall
5 moments · 2016–2025
The key moments.
2016
🌱
2016
Founded to map the human proteome
Isilon co-founder Sujal Patel and Stanford scientist Parag Mallick set out to read every protein with a single-molecule platform.
GeekWire
Jun 2021
📈
Jun 2021
The peak: a ~$1.5B SPAC debut$1.5B
Merges with Perceptive Advisors' Arya Sciences Acquisition Corp III and trades above $10 a share — before the platform has shipped.
Businesswire
2022
💔
2022
Slips out of the club
The stock sinks with the rest of the de-SPAC class of 2021, falling below a $1B value on its way to a 90%-plus drawdown.
GeekWire
2022–24
2022–24
The launch keeps receding
Commercialization targets slip year after year — eventually to late 2026 — while losses mount.
GeekWire
2025
2025
16% of staff cut
With the platform still unlaunched and the market cap around $105M, Nautilus lays off 16% of its workforce.
GeekWire
Today
Today
Still in the club — and still trading
Live · NAUT · NasdaqCMas of 2026-09-17
$0.972▼ 1.85% today≈ $124M cap · −91.8% from peak
How it happened
Nautilus Biotechnology aimed to map the entire human proteome with a single-molecule protein-analysis platform, and went public in June 2021 via a SPAC merger with Perceptive Advisors' Arya Sciences Acquisition Corp III, trading above $10 a share for a valuation over $1B.
The product proved hard to commercialize: launch timelines slipped repeatedly (now targeted for late 2026), losses mounted and the stock fell more than 90%. By 2025 Nautilus had cut 16% of staff and was worth only around $100M — a fraction of its debut.
Source: Businesswire / GeekWire / SEC (SPAC merger with Arya Sciences Acquisition Corp III, closed June 2021, traded >$10/share at >$1B; ~$105M market cap 2025; commercial platform delayed to 2026; 16% layoffs)
